LUPUS STUDY RESULTS PUBLISHED

Immunomedics has announced that results from their Phase II study of epratuzumab in systemic lupus erythematosus (SLE) have been published in the online edition of Arthritis Research & Therapy.

Fourteen patients with moderately active SLE were enrolled in this open- label, single-center study. At the beginning of the study, total baseline BILAG (British Isles Lupus Assessment Group) scores for the group ranged from 6 to 12. In all 14 patients at some point during the study, total BILAG scores decreased by 50 percent or more. Almost all patients (93 percent) experienced improvement in at least one BILAG B- or C-level disease activity at six, 10, and 18 weeks. Additionally, three patients with multiple BILAG B involvement at baseline had completely resolved all B-level disease activities by 18 weeks.